Terbium radionuclides are gaining prominence in theranostics, with 155Tb emerging as promising SPECT imaging agent due to its γ emissions (87 keV, 32%; 105 keV, 25%) and favorable half-life (T1/2=5.32 days), allowing extended biodistribution monitoring. However, efficient production via hospital cyclotrons is challenging, particularly in reducing 156Tb contamination, which affects image quality and increases patient dose. This study investigates the 155Gd(p,n)155Tb reaction, highlighting the importance of 155Gd target enrichment.
Hospital-cyclotrons production of high-purity 155Tb via 155Gd(p,n)
Barbaro, Francesca;De Nardo, Laura;
2025
Abstract
Terbium radionuclides are gaining prominence in theranostics, with 155Tb emerging as promising SPECT imaging agent due to its γ emissions (87 keV, 32%; 105 keV, 25%) and favorable half-life (T1/2=5.32 days), allowing extended biodistribution monitoring. However, efficient production via hospital cyclotrons is challenging, particularly in reducing 156Tb contamination, which affects image quality and increases patient dose. This study investigates the 155Gd(p,n)155Tb reaction, highlighting the importance of 155Gd target enrichment.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
BarbaroF_ARI2025_terbio155.pdf
accesso aperto
Tipologia:
Published (Publisher's Version of Record)
Licenza:
Creative commons
Dimensione
1.05 MB
Formato
Adobe PDF
|
1.05 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
